The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129) has launched the joint transnational call 2026 (JTC2026) “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acro-nym: CARMEN2026), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The available budget for this call is 38 Mio. € (approx.).
Main Objective: Fund research in human health focusing on personalised medicine strategies for:
- Cardiovascular diseases
- Metabolic diseases
- Kidney diseases
(Projects may address one disease or combinations of these.)
Eligible Research Topics Projects should address one or more of the following:
- Personalised Therapeutic Approaches: Develop and validate innovative treatments using relevant pre-clinical models (e.g., organoids, organs-on-chips, disease-specific animal models, in silico models).
- Treatment Monitoring: Identify and validate molecular markers or advanced technologies to monitor treatment response, optimise dosage, and assess adverse effects.
- Risk Prediction and Prevention: Identify and validate stratifying markers or diagnostic tools for early risk prediction and prevention of disease progression or comorbidities.
Collaboration Requirements:
- Interdisciplinary research: Include fields such as bioinformatics, health economics, ELSA (ethical, legal, social aspects), and implementation research.
- Cross-sector collaboration: Engage private sector (SMEs, industry), regulatory agencies, and patient organisations.
- Participatory research: Ensure active involvement of patients or citizens.
Recommended Research Approaches Projects are encouraged to integrate:
- Multi-omics data (genomics, proteomics, metabolomics, etc.) linked to treatment outcomes.
- Cutting-edge technologies: AI/ML, next-generation imaging, digital health tools.
- Patient-related information: Medication, compliance, adverse effects, patient-reported outcomes.
- Additional factors: Sex/gender, age, environment, lifestyle, nutrition.
Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations*):
A) Academia (research teams working in universities, other higher education institutions) or research institutes;
B) Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;
C) Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.
Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C). It is also strongly recommended to integrate at least one early-career researcher as principal investigator in a consortium.
* Requirements for entities from Navarra: Universities, Research Institutes, technological centers and companies that comply with points 2.2 and 2.5 a) and b) from the Resolution 466E/2024, of the 30 December. It can be found in the Official Navarrese Gazette #14, 13th February 2025 (https://bon.navarra.es/es/anuncio/-/texto/2025/30/7 ).
Eligibility criteria:
- Only transnational projects will be funded.
- Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation.
- All three legal entities must be independent of each other.
- The project coordinator must be eligible to be funded by their regional/national participating funding organisation.
- Max. 2 project partners per consortium can request funding from the same funding organisation.
- No more than one partner on own funds is allowed in the consortia with at least three partners eligible for funding.
A two-step submission and evaluation procedure has been established for joint applications. Important deadlines:
- Submission of pre-proposals: 10 February 2026 at 14:00 (CET)
- Submission of invited full proposals: 09 June 2026 at 14:00 (CEST)
In both phases, one joint proposal document shall be prepared by the partners of a joint transnational project. The document must be submitted to the JCS by the project coordinator by uploading it via the electronic submission system (https://ptoutline.eu/app/eppermed2026).